Save over 65% vs US Osphena.
Osphena is called Senshio in UK.
Information about Osphena (Ospemifene)
Osphena is a prescription medication containing ospemifene, a selective estrogen receptor modulator (SERM) used primarily to treat moderate to severe symptoms of vaginal atrophy associated with menopause. Vaginal atrophy refers to the thinning, dryness, and inflammation of the vaginal walls due to decreased estrogen levels, a common issue during and after menopause. Ospemifene acts by mimicking estrogen in certain tissues, providing relief from these symptoms without some of the risks associated with hormone replacement therapy (HRT).
Product Highlights
- Osphena is primarily indicated for:
- Painful intercourse due to vaginal atrophy in postmenopausal women. This is the main FDA-approved use.
- Associated with menopause, resulting in symptoms like vaginal dryness, burning, and irritation, which can affect sexual activity and quality of life.
Key Ingredient
Key Benefits
- Helps improve vaginal moisture, elasticity, and overall health of the vaginal tissues, reducing discomfort, dryness, and irritation.
- Provides an alternative to estrogen therapy, which may not be suitable for all women due to concerns about hormone replacement risks (e.g., blood clots, breast cancer).
- Alleviates dyspareunia (painful intercourse), improving sexual function and overall quality of life for postmenopausal women.
- Taken as a daily oral tablet, making it easy to integrate into a daily routine.
Direction of Use
- The typical recommended dose is one 60 mg tablet taken once daily with food.
- Take the tablet at the same time each day with a full glass of water. It is best taken with food to help reduce the risk of gastrointestinal upset.
- For best results, it should be taken consistently as directed by a healthcare provider.
Safety Concerns
- Like other SERMs, there may be an increased risk of endometrial changes (thickening of the uterine lining), which could potentially lead to endometrial cancer. Women with a uterus should be monitored regularly while using Osphena.
- There is an increased risk of blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in women using Osphena. Caution is advised for women with a history of blood clots.
- As with other SERMs, Osphena may increase the risk of stroke in certain women, particularly those who have other risk factors (e.g., hypertension, smoking, or a history of cardiovascular disease).
- Osphena may affect liver enzymes, so liver function should be monitored during treatment, especially in women with pre-existing liver conditions.
- Common side effects include hot flashes, vaginal discharge, muscle spasms, and sweating. Less common, but more serious side effects include vision changes, unexplained bleeding, or signs of blood clots.
Avoid Osphena (Ospemifene) If
- Women with a history of deep vein thrombosis (DVT), pulmonary embolism (PE), or stroke should avoid Osphena, as it may increase the risk of blood clot formation.
- Women with a history of endometrial cancer or other estrogen-dependent cancers should not use Osphena due to the potential for estrogen-like effects on the uterine lining.
- If you have severe liver impairment or liver disease, Osphena should be avoided or used with caution, and liver function should be monitored.
- Any unexplained vaginal bleeding should be evaluated before starting Osphena, as it could be a sign of a serious condition like endometrial cancer.
- Osphena is not recommended during pregnancy or breastfeeding due to potential risks to the fetus or infant. It is classified as a Pregnancy Category X drug (contraindicated during pregnancy).
- If you are allergic to ospemifene or any of the tablet's ingredients, you should avoid using this medication.
